Current concepts of the pathogenesis of non-alcoholic fatty liver disease
https://doi.org/10.14341/2072-0351-6018
Abstract
Non-alcoholic fatty liver disease (NAFLD) - common chronic liver disease, characterized by pathological accumulation of fat droplets, not associatedwith alcohol. NAFLD is often a component of other diseases such as metabolic syndrome, diabetes, obesity, and contributes to the prevalence of CVDamong the population.Asymptomatic disease, the difficulty of diagnosis, the lack of a unified concept of treatment NAFLD - topical issues that require more in-depth studyand worthy of attention a wide range of specialists.
About the Authors
Evgenia Pavlovna Kosobyan
Endocrinological Research Centre, Moscow
Olga Mikhailovna Smirnova
Endocrinological Research Centre, Moscow
References
1. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults // J. Clin. Gastroenterol. 2006. 40. - P. S5-1
2. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin. Proc. - 1980. - 55. - P. 434-
3. Adams L.A., Lindor K.D. Nonalcoholic fatty liver disease // Ann. Epidemiol. - 2007. - 17. - P. 863-8
4. Nahum Mйndez-Sбnchez, Marco Arrese, Daniel Zamora-Valdйs, Misael Uribe. Current Concepts in the Pathogenesis of Nonalcoholic Fatty Liver Disease // Liver Int. - 2007. - 27(4). - P. 423-
5. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? // Diabetologia. - 2008. - 51. - P. 1947-1
6. Ground K.E. Liver pathology in aircrew // Aviat. Space. Environ. Med. - 1982. - 53. - P. 14-
7. Звенигородская Л.А., Хомерики С.Г., Егорова Е.Г. Морфологические изменения печени при инсулинорез
8. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., Omatsu T., Nakajima T., Sarui H., Shimazaki M., Kato T., Okuda J., Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease // Ann. Intern. Med. - 2005. - 143. - P. 722-
9. Gupte P., Amarapurkar D., Agal S., Baijal R., Kulshrestha P., Pramanik S., Patel N., Madan A., Amarapurkar A., Hafeezunnisa. Non-alcoholic steato-hepatitis in type 2 diabetes mellitus // J. Gastroenterol. Hepatol. - 2004. - 19. - P. 854-
10. Fan J.G., Zhu J., Li X.J., Chen L., Lu Y.S., Li L., Dai F., Li F., Chen S.Y. Fatty liver and the metabolic syndrome among Shanghai adults // J. Gastroenterol. Hepatol. - 2005. - 20. - P. 1825-1
11. Angulo P. et al. Independed predictors of liver fibrosis in patients whis nonalcoholic steatohepatitis // Hepatology. - 1999. - 30. - P. 1356- 1
12. Clark J.M. The prevalense and etiology of elevated aminotransferase levels in the United States // Am. J. Gastroenterol. - 2003. - 98. - P. 955-
13. Lin Y.C., Lo H.M., Chen J.D. Sonographic fatty liver, overweight and ischemic heart disease // World J. Gastroenterol. - 2005. - 11. - P. 4838-4
14. Буеверов А.О., Маевская М.В. Некоторые патогенетические и клинические вопросы неалкогольного ст
15. Mensenkamp A.R., Havekes L.M., Romijn F. et al. Hepatic steatosis and very lowdensity lipoprotein secretion: the involvement of apolipoprotein E // J. Hepatology. - 2001. - 35(6). - P. 816-
16. Burt A.D., Mutton A., Day C.P. Diagnosis and interpretation of steatosis and steatohepatitis // Semin. Diagn. Pathol., 1998. - 15. - P. 246-2
17. Ивашкин В.Т., Драпкина О.М. Оксид азота и инфаркт миокарда // Бюл. НЦССХ им. Н.Н. Бакулева РАМН. Сердечно-сосудистые заболевания. Креативн
18. Mylonas C. et al. Lipid peroxidation and tissue damage //In vivo. - 1999. - 13. - P. 295-
19. Sanyal A.J. et al. Nonalcoholic steatohepatitis: Associations of insulin resistance whis mitohondrial abnormalities // Gastroenterology. - 2001. - 120. - P. 1183-1
20. Фадеенко Г.Д., Кравченко Н.А., Виноградова С.В. Прогноз и эффективность лечения неалкогольного стеатогепати
21. Драпкина О.М. Применение эссенциальных фосфолипидов в комплексной терапии сте
22. Драпкина О.М., Гацолаева Д.С., Калинин А.И. Применение препарата Эссливер-форте у больных с метаболическ
23. Hussain M.M., Shi J., Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly // J. Lipid. Res. - 2003. - 44. - P. 22-
24. Jackson T.K., Salhanick A.I., Elovson J., Deichman M.L., Amatruda J.M. Insulin regulates apolipoprotein B turnover and phosphorylation in rat hepatocytes // J. Clin. Invest. - 1990. - 86. - P. 1746-1
25. Osei-Hyiaman D., Depetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity // J. Clin. Invest. - 2005. - 115. - P. 1298-1
26. Cota D., Marsicano G., Tschop M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis // J. Clin. Invest. - 2003. - 112. - P. 423-
27. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity // Biochem. Biophys. Res. Commun. - 1999. - 257. - P. 79-
28. Masaki T., Chiba S., Tatsukawa H., et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice // Hepatology. - 2004. - 40. - P. 177-
29. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice // J. Clin. Invest. - 2003. - 112. - P. 91-1
30. Piero Rinaldo, Dietrich Matern Fatty Acid Oxidation Disorders and Michael J. Bennett // Annu. Rev. Physiol. - 2002. 64. - P. 477-5
31. Аrrol S., Mackness M.I., Durrington P.N. The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2) // Atherosclerosis. - 2000. - 150. - P. 255-
32. Repa J.J., Liang G., Ou J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta // Genes. Dev. - 2000. - 14. - P. 2819-2
33. Yeon J.E., Choi K.M., Baik S.H., et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease // J. Gastroenterol. Hepatol. - 2004. - 19. - P. 799-
34. Shiiya T., Nakazato M., Mizuta M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion // J. Clin. Endocrinol. Metab. - 2002. - 87. - P. 240-
35. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis // N. Engl. J. Med. - 2000. - 343. - P. 1467-1
36. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? // Hepatology. - 2004. - 40. - P. 46-
37. Harrison S.A., Torgerson S., Hayashi P. et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis // Am. J. Gastroenterol. - 2003. - Vol. 98, №11. - P. 2348-
38. Ikura Y., Ohsawa M., Shirari N. et al. Expression of angio-tensin II type peceptor in human cirrotics livers: its relation to fibrosis and portal hypertension // Hepatol. Res. - 2005. - Vol. 32. - Р. 107-
39. Targher G., Bertolini L., Padovani R., Zenari L., Zoppini G., Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation // Diabetes Care. - 2004. - 27. - P. 2498-2
40. Schindhelm R.K., Diamant M., Bakker S.J., et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus // Eur. J. Clin. Invest. - 2005. - 35(6). - P. 369-
41. Мехтиев С.Н., Гриневич В.Б., Кравчук Ю.А., Бращенкова А.В. Неалкогольная жировая болезнь печени:
42. Goland S., Shimoni S., Zornitzki T. et al Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echo-cardiographic and tissue Doppler imaging assessment // J. Clin. Gastroenterol. - 2006. - 40. - P. 949-
43. Wannamethee G., Ebrahim S., Shaper A.G. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes // Am. J. Epidemiol. - 1995. - 142. - P. 699-
44. Богомолов П.О., Павлова Т.В. Неалкогольный стеатогепатит: патоморфология, клин
45. Belentani S., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy // Ann. Intern. Med. - 2000. - 132. - P. 112-
46. Wanless I.R., et al. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors // Hepatology. - 1990. - 11. - P. 74-
47. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese // Gastroenterology. - 2001. - 121. - P. 91-
48. James O.F.W., Leuschner U., Dancygier H. Diagnosis of non-alcoholic steatohepatitis. // Steatohepatitis . - Dordrecht: Kluwer Academic Publishers, 2001. - P. 34-
49. Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver disease // CMAJ. - 2005. - 172(7). - P. 899-9
50. Joong-Won Park, Gyu Jeong, Sang Jin Kim, Mi Kyung Kim, Sill Moo Park Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients // Journal of Gastroenterology and Hepatology. - 2007. - 5. - P.
51. Medina J., Fernбndez-Salazar L.I., Garcнa-Buey L., Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis // Diabetes Care. - 2004. - Aug.; 27 (8). - P. 2057-2
52. Ariel E. Feldstein и соавторы // Hepatology. - 2006. - 44.
53. Bantel H., Ruck P., Gregor M., Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases // Eur. J. Cell. Biol. - 2001. - 80. - P. 230-
54. Afdhal N.H. and Nunes D. Evaluation of liver fibrosis: a concise review // Am. J. Gastroenterol. - 2004. -99. - P. 1160-1
55. Marceau P., et al. Liver pathology and the metabolic syndrome X in severe obesity // J. Clin. Endo. Metab. - 1999. - 84. - P. 1513-1
56. Marchesini G., Bugianesi E., Forlani G. et al Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome // Hepatology. - 2003. - 37. - P. 917-
57. Богомолов П.О., Цодиков Г.В. Неалкогольная жировая болезнь печени // Справ
58. Kleiner D.E., Brunt E.M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease //Hepatology. - 2005. - 41. - P. 1313-1
59. Ranlov I., et al. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity // Digestion. - 1990. - 47. - P. 208-
60. James O. NASH/NAFLD management. AASLD single topic Conference Nonalcoholic steatohepatitis - NASH. - P. 116-1
61. Harrison S., et al. Orlistat treatment in obese, non-alcoholic steatohepatitis patients: A pilot study. AASLD single topic Conference Nonalcoholic steatohepatitis - NASH. - P. 13
62. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis // Lancet. - 2001. - 358. - P. 893-
63. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., Yesilova Z., Gulsen M., Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis // Aliment. Pharmacol. Ther. - 2004. - 19. - P. 537-
64. Blaszyk H., Ferrentino N., Forsell S., Strader D., Lidofsky S. A Pilot Study of Metformin As Treatment for Nonalcoholic Steatohepatitis // Gastroenterology. - 2005. - 122. - P. M16
65. Nair S., Diehl A.M., Wiseman M., Farr G.H.Jr., Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial // Aliment. Pharmacol. Ther. - 2004. - 20. - P. 23-
66. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Vil-lanova N., David E., Rizzetto M., Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease // Am. J. Gastroenterol. - 2005. - 100. - P. 1082-
67. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action // J. Clin. Invest. - 2001. - 108. - P. 1167-1
68. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosigli-tazone // Hepatology. - 2003. - 38. - P. 1008-1
69. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., Doo E., Ghany M., Premkumar A., Park Y., Liang T.J., Yanovski J.A., Kleiner D.E., Hoofnagle J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis // Hepatology. - 2004. - 39. - P. 1888-1
70. Azuma T., Tomita K., Kato S., Adachi H., Inokuchi S., Kitamura N., Nishimura T., Ishii H. A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis // Hepatology. - 2002. - 28. - P. 406A
Review
For citations:
Kosobyan E.P., Smirnova O.M. Current concepts of the pathogenesis of non-alcoholic fatty liver disease. Diabetes mellitus. 2010;13(1):55-64. (In Russ.) https://doi.org/10.14341/2072-0351-6018
Views:
29336
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
